For as long as she could remember, Dina Radenkovic was a meticulous planner, determined to leave as little as possible to chance. But Radenkovic – a physician, research scientist and biotechnology investor – felt gripped by uncertainty over how to plan for one of her most long-held goals: becoming a mother. She thought about freezing her eggs, but enduring two weeks of potentially uncomfortable and nauseating injections felt impossible: It would have meant missing work.So in December 2022, Radenkovic, then 27, found herself alone in her kitchen in New York jabbing her abdomen with a needle, the first step in the arduous in vitro fertilization process. Egg retrieval alone requires roughly two weeks of daily shots that flood the body with hormones – often triggering a range of physical and emotional side effects – to induce the ovaries to produce as many mature egg follicles as possible.Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. AdvertisementAdvertisementAdvertisementAdvertisementBut Radenkovic wasn’t trying to have a baby. She was experimenting on herself in a clinical trial that aimed to alter the experience of families struggling with infertility. If everything went according to plan, this would be Radenkovic’s only hormone shot.The injection was an early chapter in what has become Gameto, Radenkovic’s six-year-old company that is on the precipice of what some experts say may be one of the most significant innovations to IVF treatment in decades. Its …
